OnabotulinumtoxinA for chronic migraine treatment: 75% responder analysis from double-blind, randomized, placebo-controlled phase of PREEMPT
Authors:
Open Access
- 21 February 2013
- journal article
- other
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 14 (S1) , P197
Abstract
No abstract availableKeywords
This publication has 1 reference indexed in Scilit:
- OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double‐Blind, Randomized, Placebo‐Controlled Phases of the PREEMPT Clinical ProgramHeadache: The Journal of Head and Face Pain, 2010